Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18621642 | 1.00 | TAAR1 (0.49) | TAAR1PREPACEALDH1A1CMA1 | |
| SCHEMBL20484748 | 0.90 | ACE (0.50) | TAAR1PREPACECMA1 | |
| SCHEMBL18619615 | 0.90 | ACE (0.50) | TAAR1PREPACECMA1 | |
| SCHEMBL22209501 | 0.88 | TAAR1 (0.49) | TAAR1PREPACEALDH1A1NPC1 | |
| SCHEMBL22811071 | 0.88 | CMA1 (0.50) | TAAR1PREPACECMA1NPC1 | |
| SCHEMBL18619644 | 0.88 | TAAR1 (0.49) | TAAR1PREPACEALDH1A1NPC1 | |
| SCHEMBL18621640 | 0.88 | PREP (0.52) | TAAR1PREPACEALDH1A1ELANE | |
| SCHEMBL22209498 | 0.88 | PREP (0.52) | TAAR1PREPACEALDH1A1ELANE | |
| SCHEMBL18620607 | 0.87 | ACE (0.57) | TAAR1PREPACEALDH1A1NPC1 | |
| SCHEMBL22209426 | 0.87 | ACE (0.57) | TAAR1PREPACEALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | TAAR1 4584/4885PREP 1162/4885ACE 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.